Evidence map›Paper›PMID 42225990›Full record

Trial reportNature medicine2026

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Zhi Peng, Tianshu Liu, Hua Wang, Jufeng Wang, Hongli Liu, Feng Ye, Enxiao Li, Jun Zhang, Baorui Liu, Rongbo Lin and 33 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04923932 (A Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients With MET Gene Amplifications), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04923932 phase2completednot on this map

A Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients With MET Gene Amplifications

TypeinterventionalSponsorHutchison Medipharma LimitedRan2021 to 2026Enrolled110ConditionsGastric Cancer, Esophagogastric Junction DisorderArmsSavolitinib
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Zhi Peng *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China. zhipeng@bjmu.edu.cn.ORCID http://orcid.org/0000-0003-4063-9813
Tianshu Liu *Department of Medical Oncology, Zhongshan Hospital, Shanghai, China.ORCID http://orcid.org/0000-0002-8604-6311
Hua Wang *Department of Medical Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Jufeng Wang *Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
Hongli LiuDepartment of Abdominal Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Feng YeDepartment of Medical Oncology, First Affiliated Hospital of Xiamen University, Xiamen, China.
Enxiao LiDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jun ZhangDepartment of Medical Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Baorui LiuDepartment of Medical Oncology, Nanjing Drum Tower Hospital, Nanjing, China.ORCID http://orcid.org/0000-0002-2539-7732
Rongbo LinDepartment of Abdominal Oncology, Fujian Cancer Hospital, Fuzhou, China.
Aiping ZhouDepartment of Medical Oncology, Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing, China.
Zhenyang LiuDepartment of Gastroenterology and Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Huiting XuDepartment of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China.
Qiong WangDepartment of Medical Oncology, Jiangyin People's Hospital, Jiangyin, China.
Zuoxing NiuDepartment of Gastrointestinal Oncology, Affiliated Cancer Hospital of Shandong First Medical University, Jinan, China.
Ying YuanDepartment of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Yanru QinDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiujuan QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.ORCID http://orcid.org/0009-0005-9366-2314
Yuxian BaiWard 1 of Gastroenterology Department, Harbin Medical University Cancer Hospital, Harbin, China.
Ning LiuDepartment of Medical Oncology, Jining First People's Hospital, Jining, China.
Hailong LiuDepartment of Medical Oncology, The First People's Hospital of Chenzhou, Chenzhou, China.
Chunmei BaiDepartment of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
Yueyin PanOncology Chemotherapy Department, Anhui Provincial Hospital, Hefei, China.
Shubin WangDepartment of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, China.
Tao WuDepartment of Medical Oncology, Anyang Tumor Hospital, Anyang, China.
Qinghua PanDepartment of Internal Medicine, Ganzhou Cancer Hospital, Ganzhou, China.
Diansheng ZhongDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.
Hongxia LuDepartment of Digestive Medicine, Shanxi Hospital Affiliated to Cancer Hospital (Shanxi Province Cancer Hospital), Taiyuan, China.
Junye WangDepartment of Medical Oncology, Affiliated Hospital of Jining Medical University, Jining, China.
Zhiyu WangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Ting DengDepartment of Gastrointestinal Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China.
Hongfeng GouDepartment of Gastric Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Xiwen HuangDepartment of Medical Oncology, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China.
Sisi FuDepartment of Research and Development, HUTCHMED, Shanghai, China.
Puhan LuDepartment of Research and Development, HUTCHMED, Shanghai, China.
Jie YuDepartment of Research and Development, HUTCHMED, Shanghai, China.
Mengyang HongDepartment of Research and Development, HUTCHMED, Shanghai, China.
Qian XuDepartment of Research and Development, HUTCHMED, Shanghai, China.
Linfang WangDepartment of Research and Development, HUTCHMED, Shanghai, China.
Yongxin RenDepartment of Research and Development, HUTCHMED, Shanghai, China.
Songhua FanDepartment of Research and Development, HUTCHMED, Shanghai, China.
Lin ShenState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China. shenlin@bjmu.edu.cn.ORCID http://orcid.org/0000-0003-1134-2922
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MET proto-oncogene amplification (METamp) is associated with poor prognosis in gastric or gastroesophageal junction (G/GEJ) cancer. Currently, effective targeted therapies for G/GEJ cancer harboring METamp remain unavailable, and clinical evidence supporting the use of MET inhibitors in this disease population is limited. Here we report the results of a phase 2 study of savolitinib, an oral MET inhibitor, in patients with METamp G/GEJ cancer. This open-label, multicenter, phase 2 trial in China comprised an exploratory phase and a pivotal phase. Patients with METamp (gene copy number ≥10 for pivotal phase), locally advanced or metastatic G/GEJ cancer that had progressed following ≥1 (≥2 for pivotal phase) prior lines of systemic therapy received savolitinib orally. The primary endpoint was objective response rate (ORR) by independent review committee in the pivotal phase. In total, 110 patients were enrolled and received savolitinib, including 45 in the exploratory phase and 65 in the pivotal phase. Independent review committee-assessed ORR was 32.3% (95% confidence interval 21.2-45.1%) in the pivotal phase, which met the predefined efficacy threshold (lower limit of 95% confidence interval of ORR ≥15%). Among all patients enrolled (n = 110), grade ≥3 treatment-related adverse events were reported in 38 patients (34.5%); one (0.9%) treatment-related death occurred. Savolitinib monotherapy showed encouraging antitumor activities and a tolerable safety profile in heavily treated, later-line METamp G/GEJ cancers, supporting further investigation in randomized controlled trials. ClinicalTrials.gov identifier: NCT04923932 .

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionProto-Oncogene Proteins c-metStomach NeoplasmsAdultAgedFemaleGene AmplificationHumansMaleMiddle AgedProtein Kinase InhibitorsProto-Oncogene MasPyrazinesTriazines1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazineMAS1 protein, humanMET protein, humanProtein Kinase InhibitorsProto-Oncogene MasProto-Oncogene Proteins c-metPyrazinesTriazines

Identifiers

PMID42225990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.